PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
Candani SA Tutuka, Miles C Andrews, John M Mariadason, Paul Ioannidis, Christopher Hudson, Jonathan Cebon, Andreas Behren
Molecular Cancer | BIOMED CENTRAL LTD | Published : 2017
Awarded by National Health & Medical Research Council of Australia Postgraduate Research Scholarship (NHMRC)
Awarded by NHMRC Research Fellowship
This research was supported by a Melanoma Research Alliance Team Science Award to JC and in part by Operational Infrastructure Support Program Funding of the Victorian State Government for the Ludwig Institute for Cancer Research. AB is supported by a Cancer Council Victoria grant, MCA is supported by a National Health & Medical Research Council of Australia Postgraduate Research Scholarship (NHMRC# 1055456), and JMM is supported by a NHMRC Research Fellowship (APP1046092).